Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.
The global Immune Checkpoint Inhibitors market size is projected to reach US$ 36030 million by 2027, from US$ 14730 million in 2020, at a CAGR of 16.1% during 2022-2027.
The global Immune Checkpoint Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Checkpoint Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Geographical Analysis:
Based on region, the global Immune Checkpoint Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Immune Checkpoint Inhibitors market are
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
Segment by Type
PD-1/PD-L1
CTLA-4
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Immune Checkpoint Inhibitors market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Immune Checkpoint Inhibitors market.
• The market share of the global Immune Checkpoint Inhibitors market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Immune Checkpoint Inhibitors market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Immune Checkpoint Inhibitors market.
The global Immune Checkpoint Inhibitors market size is projected to reach US$ 36030 million by 2027, from US$ 14730 million in 2020, at a CAGR of 16.1% during 2022-2027.
The global Immune Checkpoint Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Checkpoint Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Geographical Analysis:
Based on region, the global Immune Checkpoint Inhibitors market is segmented into North America, Europe, China, Japan, Southeast Asia India and Other regions (Middle East & Africa, Central & South America). Research analysts have studied government initiatives, changing the political environment, and social scenarios that are likely to contribute to the growth of the regional markets.
Key Players:
The major players that are operating in the global Immune Checkpoint Inhibitors market are
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc
Segment by Type
PD-1/PD-L1
CTLA-4
Segment by Application
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other
Competitive Landscape:
Factors such as cost analysis, marketing strategy, factor analysis, distributors, sourcing strategy, and industrial chain are all the parts of the global Immune Checkpoint Inhibitors market. The report also includes the analysis of the return on investment (ROI) feasibility with the estimated SWOT analysis.
The report covers the following objectives:
• Proliferation and maturation of trade in the global Immune Checkpoint Inhibitors market.
• The market share of the global Immune Checkpoint Inhibitors market, supply and demand ratio, growth revenue, supply chain analysis, and business overview.
• Current and future market trends that are influencing the growth opportunities and growth rate of the global Immune Checkpoint Inhibitors market.
• Feasibility study, new market insights, company profiles, investment return, revenue (value), and consumption (volume) of the global Immune Checkpoint Inhibitors market.
1 Immune Checkpoint Inhibitors Market Overview
1.1 Immune Checkpoint Inhibitors Product Scope
1.2 Immune Checkpoint Inhibitors Segment by Type
1.2.1 Global Immune Checkpoint Inhibitors Sales by Type (2016 & 2021 & 2027)
1.2.2 PD-1/PD-L1
1.2.3 CTLA-4
1.3 Immune Checkpoint Inhibitors Segment by Application
1.3.1 Global Immune Checkpoint Inhibitors Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancer
1.3.8 Other
1.4 Immune Checkpoint Inhibitors Market Estimates and Forecasts (2016-2027)
1.4.1 Global Immune Checkpoint Inhibitors Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Immune Checkpoint Inhibitors Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Immune Checkpoint Inhibitors Price Trends (2016-2027)
2 Immune Checkpoint Inhibitors Estimates and Forecasts by Region
2.1 Global Immune Checkpoint Inhibitors Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Immune Checkpoint Inhibitors Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
2.2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2016-2021)
2.3 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Immune Checkpoint Inhibitors Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.2 Europe Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.3 China Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.4 Japan Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.6 India Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
3 Global Immune Checkpoint Inhibitors Competition Landscape by Players
3.1 Global Top Immune Checkpoint Inhibitors Players by Sales (2016-2021)
3.2 Global Top Immune Checkpoint Inhibitors Players by Revenue (2016-2021)
3.3 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2020)
3.4 Global Immune Checkpoint Inhibitors Average Price by Company (2016-2021)
3.5 Manufacturers Immune Checkpoint Inhibitors Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Immune Checkpoint Inhibitors Market Size by Type
4.1 Global Immune Checkpoint Inhibitors Historic Market Review by Type (2016-2021)
4.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
4.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2016-2021)
4.1.3 Global Immune Checkpoint Inhibitors Price by Type (2016-2021)
4.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Type (2022-2027)
4.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2022-2027)
4.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Type (2022-2027)
5 Global Immune Checkpoint Inhibitors Market Size by Application
5.1 Global Immune Checkpoint Inhibitors Historic Market Review by Application (2016-2021)
5.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
5.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2016-2021)
5.1.3 Global Immune Checkpoint Inhibitors Price by Application (2016-2021)
5.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Application (2022-2027)
5.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2022-2027)
5.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Application (2022-2027)
6 North America Immune Checkpoint Inhibitors Market Facts & Figures
6.1 North America Immune Checkpoint Inhibitors Sales by Company
6.1.1 North America Immune Checkpoint Inhibitors Sales by Company (2016-2021)
6.1.2 North America Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
6.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Type
6.2.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
6.2.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
6.3 North America Immune Checkpoint Inhibitors Sales Breakdown by Application
6.3.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Application (2016-2021)
6.3.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Application (2022-2027)
7 Europe Immune Checkpoint Inhibitors Market Facts & Figures
7.1 Europe Immune Checkpoint Inhibitors Sales by Company
7.1.1 Europe Immune Checkpoint Inhibitors Sales by Company (2016-2021)
7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
7.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type
7.2.1 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
7.2.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
7.3 Europe Immune Checkpoint Inhibitors Sales Breakdown by Application
7.3.1 Europe 143 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 143 Sales Breakdown by Application (2022-2027)
8 China Immune Checkpoint Inhibitors Market Facts & Figures
8.1 China Immune Checkpoint Inhibitors Sales by Company
8.1.1 China Immune Checkpoint Inhibitors Sales by Company (2016-2021)
8.1.2 China Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
8.2 China Immune Checkpoint Inhibitors Sales Breakdown by Type
8.2.1 China Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
8.2.2 China Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
8.3 China Immune Checkpoint Inhibitors Sales Breakdown by Application
8.3.1 China 166 Sales Breakdown by Application (2016-2021)
8.3.2 China 166 Sales Breakdown by Application (2022-2027)
9 Japan Immune Checkpoint Inhibitors Market Facts & Figures
9.1 Japan Immune Checkpoint Inhibitors Sales by Company
9.1.1 Japan Immune Checkpoint Inhibitors Sales by Company (2016-2021)
9.1.2 Japan Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
9.2 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type
9.2.1 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
9.2.2 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
9.3 Japan Immune Checkpoint Inhibitors Sales Breakdown by Application
9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Immune Checkpoint Inhibitors Market Facts & Figures
10.1 Southeast Asia Immune Checkpoint Inhibitors Sales by Company
10.1.1 Southeast Asia Immune Checkpoint Inhibitors Sales by Company (2016-2021)
10.1.2 Southeast Asia Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
10.2 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type
10.2.1 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Application
10.3.1 Southeast Asia MT Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia MT Sales Breakdown by Application (2022-2027)
11 India Immune Checkpoint Inhibitors Market Facts & Figures
11.1 India Immune Checkpoint Inhibitors Sales by Company
11.1.1 India Immune Checkpoint Inhibitors Sales by Company (2016-2021)
11.1.2 India Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
11.2 India Immune Checkpoint Inhibitors Sales Breakdown by Type
11.2.1 India Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
11.2.2 India Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
11.3 India Immune Checkpoint Inhibitors Sales Breakdown by Application
11.3.1 India Immune Checkpoint Inhibitors Sales Breakdown by Application (2016-2021)
11.3.2 India Immune Checkpoint Inhibitors Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Immune Checkpoint Inhibitors Business
12.1 Bristol Myer Squibb
12.1.1 Bristol Myer Squibb Corporation Information
12.1.2 Bristol Myer Squibb Business Overview
12.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products Offered
12.1.5 Bristol Myer Squibb Recent Development
12.2 AstraZeneca
12.2.1 AstraZeneca Corporation Information
12.2.2 AstraZeneca Business Overview
12.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.2.4 AstraZeneca Immune Checkpoint Inhibitors Products Offered
12.2.5 AstraZeneca Recent Development
12.3 Merck & Co.
12.3.1 Merck & Co. Corporation Information
12.3.2 Merck & Co. Business Overview
12.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Merck & Co. Immune Checkpoint Inhibitors Products Offered
12.3.5 Merck & Co. Recent Development
12.4 Roche / Genentech
12.4.1 Roche / Genentech Corporation Information
12.4.2 Roche / Genentech Business Overview
12.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Roche / Genentech Immune Checkpoint Inhibitors Products Offered
12.4.5 Roche / Genentech Recent Development
12.5 Incyte Corporation
12.5.1 Incyte Corporation Corporation Information
12.5.2 Incyte Corporation Business Overview
12.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Incyte Corporation Immune Checkpoint Inhibitors Products Offered
12.5.5 Incyte Corporation Recent Development
12.6 NewLink Genetics
12.6.1 NewLink Genetics Corporation Information
12.6.2 NewLink Genetics Business Overview
12.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.6.4 NewLink Genetics Immune Checkpoint Inhibitors Products Offered
12.6.5 NewLink Genetics Recent Development
12.7 ArGEN-X
12.7.1 ArGEN-X Corporation Information
12.7.2 ArGEN-X Business Overview
12.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.7.4 ArGEN-X Immune Checkpoint Inhibitors Products Offered
12.7.5 ArGEN-X Recent Development
12.8 Seattle Genetics
12.8.1 Seattle Genetics Corporation Information
12.8.2 Seattle Genetics Business Overview
12.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Seattle Genetics Immune Checkpoint Inhibitors Products Offered
12.8.5 Seattle Genetics Recent Development
12.9 Pfizer
12.9.1 Pfizer Corporation Information
12.9.2 Pfizer Business Overview
12.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Pfizer Immune Checkpoint Inhibitors Products Offered
12.9.5 Pfizer Recent Development
12.10 MacroGenics
12.10.1 MacroGenics Corporation Information
12.10.2 MacroGenics Business Overview
12.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.10.4 MacroGenics Immune Checkpoint Inhibitors Products Offered
12.10.5 MacroGenics Recent Development
12.11 Celldex Therapeutics
12.11.1 Celldex Therapeutics Corporation Information
12.11.2 Celldex Therapeutics Business Overview
12.11.3 Celldex Therapeutics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Celldex Therapeutics Immune Checkpoint Inhibitors Products Offered
12.11.5 Celldex Therapeutics Recent Development
12.12 CureTech
12.12.1 CureTech Corporation Information
12.12.2 CureTech Business Overview
12.12.3 CureTech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.12.4 CureTech Immune Checkpoint Inhibitors Products Offered
12.12.5 CureTech Recent Development
12.13 Immutep
12.13.1 Immutep Corporation Information
12.13.2 Immutep Business Overview
12.13.3 Immutep Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Immutep Immune Checkpoint Inhibitors Products Offered
12.13.5 Immutep Recent Development
12.14 Innate Pharma
12.14.1 Innate Pharma Corporation Information
12.14.2 Innate Pharma Business Overview
12.14.3 Innate Pharma Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Innate Pharma Immune Checkpoint Inhibitors Products Offered
12.14.5 Innate Pharma Recent Development
12.15 Sorrento Therapeutics
12.15.1 Sorrento Therapeutics Corporation Information
12.15.2 Sorrento Therapeutics Business Overview
12.15.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Sorrento Therapeutics Immune Checkpoint Inhibitors Products Offered
12.15.5 Sorrento Therapeutics Recent Development
12.16 GlaxoSmithKline
12.16.1 GlaxoSmithKline Corporation Information
12.16.2 GlaxoSmithKline Business Overview
12.16.3 GlaxoSmithKline Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.16.4 GlaxoSmithKline Immune Checkpoint Inhibitors Products Offered
12.16.5 GlaxoSmithKline Recent Development
12.17 GITR, Inc
12.17.1 GITR, Inc Corporation Information
12.17.2 GITR, Inc Business Overview
12.17.3 GITR, Inc Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.17.4 GITR, Inc Immune Checkpoint Inhibitors Products Offered
12.17.5 GITR, Inc Recent Development
13 Immune Checkpoint Inhibitors Manufacturing Cost Analysis
13.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
13.4 Immune Checkpoint Inhibitors Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Immune Checkpoint Inhibitors Distributors List
14.3 Immune Checkpoint Inhibitors Customers
15 Market Dynamics
15.1 Immune Checkpoint Inhibitors Market Trends
15.2 Immune Checkpoint Inhibitors Drivers
15.3 Immune Checkpoint Inhibitors Market Challenges
15.4 Immune Checkpoint Inhibitors Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
1.1 Immune Checkpoint Inhibitors Product Scope
1.2 Immune Checkpoint Inhibitors Segment by Type
1.2.1 Global Immune Checkpoint Inhibitors Sales by Type (2016 & 2021 & 2027)
1.2.2 PD-1/PD-L1
1.2.3 CTLA-4
1.3 Immune Checkpoint Inhibitors Segment by Application
1.3.1 Global Immune Checkpoint Inhibitors Sales Comparison by Application (2016 & 2021 & 2027)
1.3.2 Lung Cancer
1.3.3 Colorectal Cancer
1.3.4 Breast Cancer
1.3.5 Prostate Cancer
1.3.6 Melanoma
1.3.7 Blood Cancer
1.3.8 Other
1.4 Immune Checkpoint Inhibitors Market Estimates and Forecasts (2016-2027)
1.4.1 Global Immune Checkpoint Inhibitors Market Size in Value Growth Rate (2016-2027)
1.4.2 Global Immune Checkpoint Inhibitors Market Size in Volume Growth Rate (2016-2027)
1.4.3 Global Immune Checkpoint Inhibitors Price Trends (2016-2027)
2 Immune Checkpoint Inhibitors Estimates and Forecasts by Region
2.1 Global Immune Checkpoint Inhibitors Market Size by Region: 2016 VS 2021 VS 2027
2.2 Global Immune Checkpoint Inhibitors Retrospective Market Scenario by Region (2016-2021)
2.2.1 Global Immune Checkpoint Inhibitors Sales Market Share by Region (2016-2021)
2.2.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Region (2016-2021)
2.3 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Region (2022-2027)
2.3.1 Global Immune Checkpoint Inhibitors Sales Estimates and Forecasts by Region (2022-2027)
2.3.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Region (2022-2027)
2.4 Geographic Market Analysis: Market Facts & Figures
2.4.1 North America Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.2 Europe Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.3 China Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.4 Japan Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.5 Southeast Asia Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
2.4.6 India Immune Checkpoint Inhibitors Estimates and Projections (2016-2027)
3 Global Immune Checkpoint Inhibitors Competition Landscape by Players
3.1 Global Top Immune Checkpoint Inhibitors Players by Sales (2016-2021)
3.2 Global Top Immune Checkpoint Inhibitors Players by Revenue (2016-2021)
3.3 Global Immune Checkpoint Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Immune Checkpoint Inhibitors as of 2020)
3.4 Global Immune Checkpoint Inhibitors Average Price by Company (2016-2021)
3.5 Manufacturers Immune Checkpoint Inhibitors Manufacturing Sites, Area Served, Product Type
3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Immune Checkpoint Inhibitors Market Size by Type
4.1 Global Immune Checkpoint Inhibitors Historic Market Review by Type (2016-2021)
4.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Type (2016-2021)
4.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Type (2016-2021)
4.1.3 Global Immune Checkpoint Inhibitors Price by Type (2016-2021)
4.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Type (2022-2027)
4.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Type (2022-2027)
4.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Type (2022-2027)
4.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Type (2022-2027)
5 Global Immune Checkpoint Inhibitors Market Size by Application
5.1 Global Immune Checkpoint Inhibitors Historic Market Review by Application (2016-2021)
5.1.1 Global Immune Checkpoint Inhibitors Sales Market Share by Application (2016-2021)
5.1.2 Global Immune Checkpoint Inhibitors Revenue Market Share by Application (2016-2021)
5.1.3 Global Immune Checkpoint Inhibitors Price by Application (2016-2021)
5.2 Global Immune Checkpoint Inhibitors Market Estimates and Forecasts by Application (2022-2027)
5.2.1 Global Immune Checkpoint Inhibitors Sales Forecast by Application (2022-2027)
5.2.2 Global Immune Checkpoint Inhibitors Revenue Forecast by Application (2022-2027)
5.2.3 Global Immune Checkpoint Inhibitors Price Forecast by Application (2022-2027)
6 North America Immune Checkpoint Inhibitors Market Facts & Figures
6.1 North America Immune Checkpoint Inhibitors Sales by Company
6.1.1 North America Immune Checkpoint Inhibitors Sales by Company (2016-2021)
6.1.2 North America Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
6.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Type
6.2.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
6.2.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
6.3 North America Immune Checkpoint Inhibitors Sales Breakdown by Application
6.3.1 North America Immune Checkpoint Inhibitors Sales Breakdown by Application (2016-2021)
6.3.2 North America Immune Checkpoint Inhibitors Sales Breakdown by Application (2022-2027)
7 Europe Immune Checkpoint Inhibitors Market Facts & Figures
7.1 Europe Immune Checkpoint Inhibitors Sales by Company
7.1.1 Europe Immune Checkpoint Inhibitors Sales by Company (2016-2021)
7.1.2 Europe Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
7.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type
7.2.1 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
7.2.2 Europe Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
7.3 Europe Immune Checkpoint Inhibitors Sales Breakdown by Application
7.3.1 Europe 143 Sales Breakdown by Application (2016-2021)
7.3.2 Europe 143 Sales Breakdown by Application (2022-2027)
8 China Immune Checkpoint Inhibitors Market Facts & Figures
8.1 China Immune Checkpoint Inhibitors Sales by Company
8.1.1 China Immune Checkpoint Inhibitors Sales by Company (2016-2021)
8.1.2 China Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
8.2 China Immune Checkpoint Inhibitors Sales Breakdown by Type
8.2.1 China Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
8.2.2 China Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
8.3 China Immune Checkpoint Inhibitors Sales Breakdown by Application
8.3.1 China 166 Sales Breakdown by Application (2016-2021)
8.3.2 China 166 Sales Breakdown by Application (2022-2027)
9 Japan Immune Checkpoint Inhibitors Market Facts & Figures
9.1 Japan Immune Checkpoint Inhibitors Sales by Company
9.1.1 Japan Immune Checkpoint Inhibitors Sales by Company (2016-2021)
9.1.2 Japan Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
9.2 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type
9.2.1 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
9.2.2 Japan Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
9.3 Japan Immune Checkpoint Inhibitors Sales Breakdown by Application
9.3.1 Japan Mar. Sales Breakdown by Application (2016-2021)
9.3.2 Japan Mar. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Immune Checkpoint Inhibitors Market Facts & Figures
10.1 Southeast Asia Immune Checkpoint Inhibitors Sales by Company
10.1.1 Southeast Asia Immune Checkpoint Inhibitors Sales by Company (2016-2021)
10.1.2 Southeast Asia Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
10.2 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type
10.2.1 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
10.2.2 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
10.3 Southeast Asia Immune Checkpoint Inhibitors Sales Breakdown by Application
10.3.1 Southeast Asia MT Sales Breakdown by Application (2016-2021)
10.3.2 Southeast Asia MT Sales Breakdown by Application (2022-2027)
11 India Immune Checkpoint Inhibitors Market Facts & Figures
11.1 India Immune Checkpoint Inhibitors Sales by Company
11.1.1 India Immune Checkpoint Inhibitors Sales by Company (2016-2021)
11.1.2 India Immune Checkpoint Inhibitors Revenue by Company (2016-2021)
11.2 India Immune Checkpoint Inhibitors Sales Breakdown by Type
11.2.1 India Immune Checkpoint Inhibitors Sales Breakdown by Type (2016-2021)
11.2.2 India Immune Checkpoint Inhibitors Sales Breakdown by Type (2022-2027)
11.3 India Immune Checkpoint Inhibitors Sales Breakdown by Application
11.3.1 India Immune Checkpoint Inhibitors Sales Breakdown by Application (2016-2021)
11.3.2 India Immune Checkpoint Inhibitors Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Immune Checkpoint Inhibitors Business
12.1 Bristol Myer Squibb
12.1.1 Bristol Myer Squibb Corporation Information
12.1.2 Bristol Myer Squibb Business Overview
12.1.3 Bristol Myer Squibb Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Bristol Myer Squibb Immune Checkpoint Inhibitors Products Offered
12.1.5 Bristol Myer Squibb Recent Development
12.2 AstraZeneca
12.2.1 AstraZeneca Corporation Information
12.2.2 AstraZeneca Business Overview
12.2.3 AstraZeneca Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.2.4 AstraZeneca Immune Checkpoint Inhibitors Products Offered
12.2.5 AstraZeneca Recent Development
12.3 Merck & Co.
12.3.1 Merck & Co. Corporation Information
12.3.2 Merck & Co. Business Overview
12.3.3 Merck & Co. Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Merck & Co. Immune Checkpoint Inhibitors Products Offered
12.3.5 Merck & Co. Recent Development
12.4 Roche / Genentech
12.4.1 Roche / Genentech Corporation Information
12.4.2 Roche / Genentech Business Overview
12.4.3 Roche / Genentech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.4.4 Roche / Genentech Immune Checkpoint Inhibitors Products Offered
12.4.5 Roche / Genentech Recent Development
12.5 Incyte Corporation
12.5.1 Incyte Corporation Corporation Information
12.5.2 Incyte Corporation Business Overview
12.5.3 Incyte Corporation Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.5.4 Incyte Corporation Immune Checkpoint Inhibitors Products Offered
12.5.5 Incyte Corporation Recent Development
12.6 NewLink Genetics
12.6.1 NewLink Genetics Corporation Information
12.6.2 NewLink Genetics Business Overview
12.6.3 NewLink Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.6.4 NewLink Genetics Immune Checkpoint Inhibitors Products Offered
12.6.5 NewLink Genetics Recent Development
12.7 ArGEN-X
12.7.1 ArGEN-X Corporation Information
12.7.2 ArGEN-X Business Overview
12.7.3 ArGEN-X Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.7.4 ArGEN-X Immune Checkpoint Inhibitors Products Offered
12.7.5 ArGEN-X Recent Development
12.8 Seattle Genetics
12.8.1 Seattle Genetics Corporation Information
12.8.2 Seattle Genetics Business Overview
12.8.3 Seattle Genetics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.8.4 Seattle Genetics Immune Checkpoint Inhibitors Products Offered
12.8.5 Seattle Genetics Recent Development
12.9 Pfizer
12.9.1 Pfizer Corporation Information
12.9.2 Pfizer Business Overview
12.9.3 Pfizer Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.9.4 Pfizer Immune Checkpoint Inhibitors Products Offered
12.9.5 Pfizer Recent Development
12.10 MacroGenics
12.10.1 MacroGenics Corporation Information
12.10.2 MacroGenics Business Overview
12.10.3 MacroGenics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.10.4 MacroGenics Immune Checkpoint Inhibitors Products Offered
12.10.5 MacroGenics Recent Development
12.11 Celldex Therapeutics
12.11.1 Celldex Therapeutics Corporation Information
12.11.2 Celldex Therapeutics Business Overview
12.11.3 Celldex Therapeutics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Celldex Therapeutics Immune Checkpoint Inhibitors Products Offered
12.11.5 Celldex Therapeutics Recent Development
12.12 CureTech
12.12.1 CureTech Corporation Information
12.12.2 CureTech Business Overview
12.12.3 CureTech Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.12.4 CureTech Immune Checkpoint Inhibitors Products Offered
12.12.5 CureTech Recent Development
12.13 Immutep
12.13.1 Immutep Corporation Information
12.13.2 Immutep Business Overview
12.13.3 Immutep Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.13.4 Immutep Immune Checkpoint Inhibitors Products Offered
12.13.5 Immutep Recent Development
12.14 Innate Pharma
12.14.1 Innate Pharma Corporation Information
12.14.2 Innate Pharma Business Overview
12.14.3 Innate Pharma Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.14.4 Innate Pharma Immune Checkpoint Inhibitors Products Offered
12.14.5 Innate Pharma Recent Development
12.15 Sorrento Therapeutics
12.15.1 Sorrento Therapeutics Corporation Information
12.15.2 Sorrento Therapeutics Business Overview
12.15.3 Sorrento Therapeutics Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.15.4 Sorrento Therapeutics Immune Checkpoint Inhibitors Products Offered
12.15.5 Sorrento Therapeutics Recent Development
12.16 GlaxoSmithKline
12.16.1 GlaxoSmithKline Corporation Information
12.16.2 GlaxoSmithKline Business Overview
12.16.3 GlaxoSmithKline Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.16.4 GlaxoSmithKline Immune Checkpoint Inhibitors Products Offered
12.16.5 GlaxoSmithKline Recent Development
12.17 GITR, Inc
12.17.1 GITR, Inc Corporation Information
12.17.2 GITR, Inc Business Overview
12.17.3 GITR, Inc Immune Checkpoint Inhibitors Sales, Revenue and Gross Margin (2016-2021)
12.17.4 GITR, Inc Immune Checkpoint Inhibitors Products Offered
12.17.5 GITR, Inc Recent Development
13 Immune Checkpoint Inhibitors Manufacturing Cost Analysis
13.1 Immune Checkpoint Inhibitors Key Raw Materials Analysis
13.1.1 Key Raw Materials
13.1.2 Key Raw Materials Price Trend
13.1.3 Key Suppliers of Raw Materials
13.2 Proportion of Manufacturing Cost Structure
13.3 Manufacturing Process Analysis of Immune Checkpoint Inhibitors
13.4 Immune Checkpoint Inhibitors Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
14.1 Marketing Channel
14.2 Immune Checkpoint Inhibitors Distributors List
14.3 Immune Checkpoint Inhibitors Customers
15 Market Dynamics
15.1 Immune Checkpoint Inhibitors Market Trends
15.2 Immune Checkpoint Inhibitors Drivers
15.3 Immune Checkpoint Inhibitors Market Challenges
15.4 Immune Checkpoint Inhibitors Market Restraints
16 Research Findings and Conclusion
17 Appendix
17.1 Research Methodology
17.1.1 Methodology/Research Approach
17.1.2 Data Source
17.2 Author List
17.3 Disclaimer
